<DOC>
	<DOCNO>NCT01576458</DOCNO>
	<brief_summary>The purpose study examine efficacy safety ursodeoxycholic acid ( UDCA ) treatment patient intrahepatic cholestasis pregnancy ( ICP ) . In randomised ( double-blind , placebo-controlled ) study 20 pregnant woman ICP receive ( random allocation ) either 450 mg/day UDCA placebo 14 day third trim pregnancy . The severity pruritus register . Itching score serum level alanine aminotransferase , total bile acid , estradiol , progesterone , prolactin , cholesterol , HDL-cholesterol , triglyceride , activate partial thromboplastin time ( APTT ) , fibrinogen D-dimers ( FIDD ) platelet count assess treatment weekly thereafter . Data pregnancy delivery outcome record analyse .</brief_summary>
	<brief_title>Ursodeoxycholic Acid Treatment Intrahepatic Cholestasis Pregnancy</brief_title>
	<detailed_description />
	<mesh_term>Cholestasis</mesh_term>
	<mesh_term>Cholestasis , Intrahepatic</mesh_term>
	<mesh_term>Pregnancy Complications</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<criteria>Pregnant woman intrahepatic cholestasis pregnancy</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>ursodeoxycholic acid</keyword>
	<keyword>intrahepatic cholestasis</keyword>
	<keyword>pregnancy</keyword>
</DOC>